Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy

Approximately two‐thirds of Duchenne muscular dystrophy (DMD) patients show intragenic deletions ranging from one to several exons of the DMD gene and leading to a premature stop codon. Other deletions that maintain the translational reading frame of the gene result in the milder Becker muscular dystrophy (BMD) form of the disease. Thus the opportunity to transform a DMD phenotype into a BMD phenotype appeared as a new treatment strategy with the development of antisense oligonucleotides technology, which is able to induce an exon skipping at the pre‐mRNA level in order to restore an open reading frame. Because the DMD gene contains 79 exons, thousands of potential transcripts could be produced by exon skipping and should be investigated. The conventional approach considers skipping of a single exon. Here we report the comparison of single‐ and multiple‐exon skipping strategies based on bioinformatic analysis. By using the Universal Mutation Database (UMD)‐DMD, we predict that an optimal multiexon skipping leading to the del45‐55 artificial dystrophin (c.6439_8217del) could transform the DMD phenotype into the asymptomatic or mild BMD phenotype. This multiple‐exon skipping could theoretically rescue up to 63% of DMD patients with a deletion, while the optimal monoskipping of exon 51 would rescue only 16% of patients. Hum Mutat 28(2), 196–202, 2007. © 2006 Wiley‐Liss, Inc.

[1]  J. Faulkner,et al.  Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. , 1995, Human molecular genetics.

[2]  R. Kapsa,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group. Molecular Pathology of Dmd Novel Therapies for Dmd Novel Therapies for Duchenne Muscular Dystrophy , 2022 .

[3]  L. Kunkel,et al.  The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. , 1989, American journal of human genetics.

[4]  A. Monaco,et al.  The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein , 1988, Cell.

[5]  P. Iversen,et al.  Induction of revertant fibres in the mdx mouse using antisense oligonucleotides , 2006, Genetic vaccines and therapy.

[6]  Luis Garcia,et al.  Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping , 2004, Science.

[7]  N. Bresolin,et al.  Transcriptional activation of the non-muscle, full-length dystrophin isoforms in Duchenne muscular dystrophy skeletal muscle , 2001, Journal of the Neurological Sciences.

[8]  F. Mechler,et al.  Deletion patterns of dystrophin gene in Hungarian patients with Duchenne/Becker muscular dystrophies , 1999, Neuromuscular Disorders.

[9]  Christopher B. Burge,et al.  RESCUE-ESE identifies candidate exonic splicing enhancers in vertebrate exons , 2004, Nucleic Acids Res..

[10]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[11]  G. Kobinger,et al.  Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. , 2003, Human gene therapy.

[12]  C Béroud,et al.  UMD (Universal Mutation Database): A generic software to build and analyze locus‐specific databases , 2000, Human mutation.

[13]  M. Koenig,et al.  Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals , 1987, Cell.

[14]  G. V. Ommen,et al.  Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells , 2004, Gene Therapy.

[15]  Thierry Soussi,et al.  UMD (Universal Mutation Database): 2005 update , 2005, Human mutation.

[16]  Jinhua Wang,et al.  ESEfinder: a web resource to identify exonic splicing enhancers , 2003, Nucleic Acids Res..

[17]  G. Crawford,et al.  Suppression of revertant fibers in mdx mice by expression of a functional dystrophin. , 2001, Human molecular genetics.

[18]  L. Anderson,et al.  Multiplex Western blotting system for the analysis of muscular dystrophy proteins. , 1999, The American journal of pathology.

[19]  A. Monaco,et al.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. , 1988, Genomics.

[20]  G. van Ommen,et al.  Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. , 2004, American journal of human genetics.

[21]  A. Bornemann,et al.  Diagnostic Protein Expression in Human Muscle Biopsies , 2000, Brain pathology.

[22]  A. Speer,et al.  Alternative splicing of dystrophin mRNA complicates carrier determination: report of a DMD family. , 1993, Journal of medical genetics.

[23]  Y. Takeshima,et al.  Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon. , 2004, Human gene therapy.

[24]  L. Chasin,et al.  Computational definition of sequence motifs governing constitutive exon splicing. , 2004, Genes & development.

[25]  J. Léger,et al.  Monoclonal antibodies targeted against the C‐terminal domain of dystrophin or utrophin , 1993, FEBS letters.

[26]  N. Laing,et al.  Dystrophin gene transcripts skipping the mdx mutation , 1997, Muscle & nerve.

[27]  A. Rabinowitz,et al.  Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  J. Chamberlain,et al.  Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin , 2005, Gene Therapy.

[29]  S. Takeda,et al.  AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  Gene W. Yeo,et al.  Systematic Identification and Analysis of Exonic Splicing Silencers , 2004, Cell.

[31]  S. Harper,et al.  Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  S. Takeda.  [Current status and perspective of gene therapy on dystrophic animal model]. , 2004, Rinsho shinkeigaku = Clinical neurology.

[33]  H Sugita,et al.  Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. , 1991, American journal of human genetics.

[34]  N. Bresolin,et al.  Silencer elements as possible inhibitors of pseudoexon splicing. , 2004, Nucleic acids research.

[35]  I. Fokkema,et al.  LOVD: Easy creation of a locus‐specific sequence variation database using an “LSDB‐in‐a‐box” approach , 2005, Human mutation.